Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Oncoimmunity AS currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active matter is assigned to 1 distinct examiner working within 1 distinct art unit. The concentration of the portfolio indicates that the current prosecution strategy for the company rests with the assigned individual. This interaction with 1 distinct examiner means that the requirements of the assigned official will impact the company's overall patent success. Practitioners should focus on the technical standards prevalent in the Biotechnology & Pharmaceuticals sector to ensure the claims meet the necessary requirements for allowance.
PULLIAM, JOSEPH CONSTANTINE is identified as the busiest examiner for this portfolio, currently handling 1 pending office action. Monitoring the specific tendencies and past rulings of this examiner is necessary since there are no other active matters to provide a context for the company's standing at the office. Success in this technology area will require a response to the specific concerns raised in this pending action. Legal teams should prioritize understanding the standards of the 1 distinct art unit to effectively address this matter and ensure the application moves toward allowance. Because the busiest examiner is managing 1 pending action, the workload is limited to this matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PULLIAM, JOSEPH CONSTANTINE | 1 | 38.5% | +33.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16096997 | Machine Learning Algorithm for Identifying Peptides that Contain Features Positively Associated with Natural Endogenous or Exogenous Cellular Processing, Transportation and Histocompatibility Complex (MHC) Presentation | PULLIAM, JOSEPH CONSTANTINE | 56d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16096997 | Machine Learning Algorithm for Identifying Peptides that Contain Features Positively Associated with Natural Endogenous or Exogenous Cellular Processing, Transportation and Histocompatibility Complex (MHC) Presentation | PULLIAM, JOSEPH CONSTANTINE | 56d overdue |
| Art Unit | Apps |
|---|---|
| 1687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16096997 | Machine Learning Algorithm for Identifying Peptides that Contain Features Positively Associated with Natural Endogenous or Exogenous Cellular Processing, Transportation and Histocompatibility Complex (MHC) Presentation | PULLIAM, JOSEPH CONSTANTINE | 1687 | §101§103 | Final Rejection | 56d overdue | Pending | Oct 26, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOncoimmunity AS has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Joseph Constantine Pulliam has the most, with 1 of Oncoimmunity AS's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
